Genereach Biotechnology Stock Net Income
| 4171 Stock | TWD 27.25 1.10 3.88% |
GeneReach Biotechnology fundamentals help investors to digest information that contributes to GeneReach Biotechnology's financial success or failures. It also enables traders to predict the movement of GeneReach Stock. The fundamental analysis module provides a way to measure GeneReach Biotechnology's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to GeneReach Biotechnology stock.
GeneReach |
GeneReach Biotechnology Company Net Income Analysis
GeneReach Biotechnology's Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current GeneReach Biotechnology Net Income | 376.62 M |
Most of GeneReach Biotechnology's fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, GeneReach Biotechnology is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, GeneReach Biotechnology reported net income of 376.62 M. This is 10.35% higher than that of the Healthcare sector and significantly higher than that of the Biotechnology industry. The net income for all Taiwan stocks is 34.04% higher than that of the company.
GeneReach Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses GeneReach Biotechnology's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of GeneReach Biotechnology could also be used in its relative valuation, which is a method of valuing GeneReach Biotechnology by comparing valuation metrics of similar companies.GeneReach Biotechnology is currently under evaluation in net income category among its peers.
GeneReach Fundamentals
| Return On Equity | 0.3 | |||
| Return On Asset | 0.13 | |||
| Profit Margin | 0.38 % | |||
| Operating Margin | 0.43 % | |||
| Current Valuation | 2.09 B | |||
| Shares Outstanding | 45.97 M | |||
| Shares Owned By Insiders | 34.96 % | |||
| Shares Owned By Institutions | 4.57 % | |||
| Price To Earning | 8.39 X | |||
| Price To Book | 2.37 X | |||
| Price To Sales | 2.88 X | |||
| Revenue | 1.01 B | |||
| Gross Profit | 746.98 M | |||
| EBITDA | 535.64 M | |||
| Net Income | 376.62 M | |||
| Cash And Equivalents | 811.4 M | |||
| Cash Per Share | 17.65 X | |||
| Total Debt | 217.39 M | |||
| Debt To Equity | 0.30 % | |||
| Current Ratio | 5.21 X | |||
| Book Value Per Share | 24.36 X | |||
| Cash Flow From Operations | 348.99 M | |||
| Earnings Per Share | 6.90 X | |||
| Number Of Employees | 16 | |||
| Beta | 0.63 | |||
| Market Capitalization | 2.73 B | |||
| Total Asset | 1.68 B | |||
| Z Score | 7.2 | |||
| Annual Yield | 0.08 % | |||
| Net Asset | 1.68 B | |||
| Last Dividend Paid | 4.55 |
About GeneReach Biotechnology Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze GeneReach Biotechnology's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of GeneReach Biotechnology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of GeneReach Biotechnology based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with GeneReach Biotechnology
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if GeneReach Biotechnology position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in GeneReach Biotechnology will appreciate offsetting losses from the drop in the long position's value.Moving together with GeneReach Stock
| 0.76 | 4743 | Oneness Biotech | PairCorr |
| 0.85 | 6547 | Medigen Vaccine Biologics | PairCorr |
| 0.9 | 4174 | OBI Pharma | PairCorr |
Moving against GeneReach Stock
| 0.78 | 0050 | YuantaP shares Taiwan | PairCorr |
| 0.74 | 0057 | Fubon MSCI Taiwan | PairCorr |
| 0.63 | 0053 | YuantaP shares Taiwan | PairCorr |
| 0.59 | 2609 | Yang Ming Marine | PairCorr |
| 0.56 | 4162 | PharmaEngine | PairCorr |
The ability to find closely correlated positions to GeneReach Biotechnology could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace GeneReach Biotechnology when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back GeneReach Biotechnology - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling GeneReach Biotechnology to buy it.
The correlation of GeneReach Biotechnology is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as GeneReach Biotechnology moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if GeneReach Biotechnology moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for GeneReach Biotechnology can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for GeneReach Stock Analysis
When running GeneReach Biotechnology's price analysis, check to measure GeneReach Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GeneReach Biotechnology is operating at the current time. Most of GeneReach Biotechnology's value examination focuses on studying past and present price action to predict the probability of GeneReach Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GeneReach Biotechnology's price. Additionally, you may evaluate how the addition of GeneReach Biotechnology to your portfolios can decrease your overall portfolio volatility.